No results for ‘’
Pharmaids Pharmaceuticals Ltd
₹29.99
(0.84%)
Sat, 26 Sept 2026, 05:58 am
Health Technology
Pharmaceuticals: Major
24.5KPharmaids Pharmaceuticals Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 26.36 | 19.33 | 0 | 0 | 0 | 11.88 | 0 | 0 | 138.46 | 123.54 | 88.85 | 0 | 0 | 0 |
| Price to book ratio | 0 | 0.55 | 0.77 | 0.36 | 0.44 | 1 | 0.48 | 0.47 | 0.47 | 0.61 | 1.46 | 0.94 | 0.94 | 0.58 | 0.55 | 1.37 | 1.50 | 2.10 | 2.55 | 4.09 |
| Price to sales ratio | 14.46 | 3.15 | 4.16 | 2.19 | 1.97 | 2.71 | 0.81 | 0.78 | 0.60 | 0.58 | 1.09 | 1.08 | 2.06 | 8.67 | 0 | 1.35 | 3.27 | 0 | 7.82 | 12.45 |
| Price to cash flow ratio | 0 | 0 | 20 | 21.39 | 17.70 | 17.63 | 3.98 | 5.87 | 10.90 | 4.78 | 0 | 4.35 | 0 | 0 | 0 | 28.44 | 0 | 0 | 0 | 0 |
| Enterprise value | 0 | 2.5Cr | 2.9Cr | 1.8Cr | 1.89Cr | 2.87Cr | 1.51Cr | 1.35Cr | 1.06Cr | 1.11Cr | 2.14Cr | 0.69Cr | 0.69Cr | 4.75Cr | 4.62Cr | 11.33Cr | 12.49Cr | 12.07Cr | 120Cr | 275Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 0 | 0 | 11.20 | 17.80 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 95.98 | 91.12 | 0 | 0 | 0 |
| Debt to equity ratio | 0 | 0.42 | 0.44 | 0.44 | 0.46 | 0.48 | 0.27 | 0.24 | 0.20 | 0.18 | 0.38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.12 | 0.66 |
| Return on equity % | 0 | 0 | -7.64 | -4.63 | -5.50 | -5.17 | 1.80 | 2.50 | -18.51 | -3.83 | -27.23 | 8.34 | -32.75 | -3.80 | 0.73 | 1.11 | 1.71 | -48.85 | -16.89 | -16.43 |
Pharmaids Pharmaceuticals Ltd Enterprise Value
The Pharmaids Pharmaceuticals Ltd Enterprise Value is a key financial metric used by investors to evaluate Pharmaids Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Pharmaids Pharmaceuticals Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Pharmaids Pharmaceuticals Ltd (NSE: , BSE: 524572) is currently trading at ₹29.99, with a market capitalization of ₹104.89Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Pharmaids Pharmaceuticals Ltd Enterprise Value is essential for fundamental analysis.
Pharmaids Pharmaceuticals Ltd Enterprise Value Current Value
The current Pharmaids Pharmaceuticals Ltd Enterprise Value stands at 275Cr.
The latest Pharmaids Pharmaceuticals Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Pharmaids Pharmaceuticals Ltd Enterprise Value Historical Trend
The Pharmaids Pharmaceuticals Ltd Enterprise Value has shown the following historical trend:
- 2024: 275Cr
- 2023: 120Cr
- 2022: 12.07Cr
- 2021: 12.49Cr
- 2020: 11.33Cr
The recent rise in Pharmaids Pharmaceuticals Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Pharmaids Pharmaceuticals Ltd Enterprise Value Indicates for Investors
The Pharmaids Pharmaceuticals Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Pharmaids Pharmaceuticals Ltd.
Pharmaids Pharmaceuticals Ltd Enterprise Value Analysis Summary
The Pharmaids Pharmaceuticals Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Pharmaids Pharmaceuticals Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Pharmaids Pharmaceuticals Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.